Vifor Pharma
Launch date
Employees
Market cap
€9.0b
Enterprise valuation
€8.7b (Public information from Jan 2023)
Share price
CHF166.15 VIFN.SW
St. Gallen Canton of St. Gallen (HQ)
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 1.1b | 1.3b | 1.6b | 1.4b | 1.5b | 1.6b | 1.9b |
| % growth | - | 18 % | 18 % | (9 %) | 3 % | 12 % | 15 % |
| EBITDA | 233m | 327m | 450m | 480m | 502m | 573m | 667m |
| % EBITDA margin | 21 % | 25 % | 29 % | 34 % | 34 % | 35 % | 36 % |
| Profit | 956m | 127m | 133m | 300m | 221m | 253m | 313m |
| % profit margin | 85 % | 10 % | 8 % | 21 % | 15 % | 15 % | 17 % |
| EV / revenue | 5.9x | 4.3x | 6.2x | 5.2x | 6.0x | 5.0x | - |
| EV / EBITDA | 28.4x | 17.2x | 21.4x | 15.3x | 17.5x | 14.3x | - |
| R&D budget | 160m | 181m | 207m | - | - | - | - |
| R&D % of revenue | 14 % | 14 % | 13 % | - | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | IPO | |
* | $11.7b Valuation: $11.7b 7.5x EV/LTM Revenues 22.1x EV/LTM EBITDA | Acquisition | |
| Total Funding | - | ||
